XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Down 55.2% in August

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) was the target of a significant decline in short interest in August. As of August 14th, there was short interest totaling 10,999 shares, a decline of 55.2% from the July 30th total of 24,556 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average daily trading volume, of 5,965 shares, the days-to-cover ratio is presently 1.8 days.

XTL Biopharmaceuticals Stock Performance

Shares of XTLB stock opened at $2.47 on Friday. XTL Biopharmaceuticals has a one year low of $2.01 and a one year high of $10.28. The company’s 50-day simple moving average is $2.79 and its 200-day simple moving average is $2.73. The stock has a market capitalization of $5.43 million, a price-to-earnings ratio of -3.86 and a beta of 1.46.

Get XTL Biopharmaceuticals alerts:

XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The company had revenue of ($0.26) million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Analysis on XTLB

XTL Biopharmaceuticals Company Profile

(Get Free Report)

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Featured Stories

• Five stocks we like better than XTL Biopharmaceuticals
• 3 AI Infrastructure Stocks to Watch Beyond NVIDIA
• From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
• These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
• Venture Into High-Volatility Corners of the Market With These 3 ETFs

Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.